We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Buy Disney (DIS) Stock on the Dip After CEO Bob Iger Steps Down?
Read MoreHide Full Article
Disney (DIS - Free Report) announced Tuesday that long-time CEO Robert Iger will step down after over 14 years at the helm. Disney seemed to catch some investors off guard, with the stock falling since the news, which is clouded by the broader market-wide selloff.
Disney said that its head of parks and resorts, Bob Chapek will take over the top job, effective immediately. Chapek has been with Disney since 1993 and joins a long-line of insider CEOs at Disney. “His success over the past 27 years reflects his visionary leadership and the strong business growth and stellar results he has consistently achieved in his roles at Parks, Consumer Products and the Studio,” Iger said of Chapek in prepared remarks.
Investors should note that the 69-year-old Iger was already planning to walk away at the end of 2021. And now he will stay on to run Disney’s “creative endeavors” until his contract is up.
Iger will likely go down as one of the most successful CEOs in entertainment history. His tenure saw Disney transform through acquisitions, including Pixar, Marvel, and Lucasfilm
He also helped lead the charge on its $71 billion deal to acquire key Fox entertainment assets. All of these deals led to Iger’s final act as Disney’s chief executive: overseeing the launch of ESPN+ and Disney+.
Disney is now ready to compete for streaming TV supremacy against Netflix (NFLX - Free Report) , AT&T (T - Free Report) , Apple (AAPL - Free Report) , Amazon (AMZN - Free Report) and others. The company is also one of the most diverse entertainment firms in the world, with parks, box-office, cable and broadcast TV, and streaming.
DIS stock is currently a Zacks Rank #2 (Buy) that has seen its longer-term earnings estimates climb. Looking ahead, Disney’s sales are projected to jump 17% and 8%, respectively over the next two years.
Shares of DIS are down 17% in the last three months, which might set up a better buying opportunity for those high on the stock. In the end, Disney appears to be a solid long-term buy that also pays a dividend and might be the best-positioned company for the streaming age.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Buy Disney (DIS) Stock on the Dip After CEO Bob Iger Steps Down?
Disney (DIS - Free Report) announced Tuesday that long-time CEO Robert Iger will step down after over 14 years at the helm. Disney seemed to catch some investors off guard, with the stock falling since the news, which is clouded by the broader market-wide selloff.
Disney said that its head of parks and resorts, Bob Chapek will take over the top job, effective immediately. Chapek has been with Disney since 1993 and joins a long-line of insider CEOs at Disney. “His success over the past 27 years reflects his visionary leadership and the strong business growth and stellar results he has consistently achieved in his roles at Parks, Consumer Products and the Studio,” Iger said of Chapek in prepared remarks.
Investors should note that the 69-year-old Iger was already planning to walk away at the end of 2021. And now he will stay on to run Disney’s “creative endeavors” until his contract is up.
Iger will likely go down as one of the most successful CEOs in entertainment history. His tenure saw Disney transform through acquisitions, including Pixar, Marvel, and Lucasfilm
He also helped lead the charge on its $71 billion deal to acquire key Fox entertainment assets. All of these deals led to Iger’s final act as Disney’s chief executive: overseeing the launch of ESPN+ and Disney+.
Disney is now ready to compete for streaming TV supremacy against Netflix (NFLX - Free Report) , AT&T (T - Free Report) , Apple (AAPL - Free Report) , Amazon (AMZN - Free Report) and others. The company is also one of the most diverse entertainment firms in the world, with parks, box-office, cable and broadcast TV, and streaming.
DIS stock is currently a Zacks Rank #2 (Buy) that has seen its longer-term earnings estimates climb. Looking ahead, Disney’s sales are projected to jump 17% and 8%, respectively over the next two years.
Shares of DIS are down 17% in the last three months, which might set up a better buying opportunity for those high on the stock. In the end, Disney appears to be a solid long-term buy that also pays a dividend and might be the best-positioned company for the streaming age.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>